Article

Kala Pharmaceuticals to Present Phase 1b Clinical Data for KPI-012 in Patients with PCED at 2022 ARVO Annual Meeting

The data support the ongoing development of KPI-012, a novel investigational secretome therapy, to address the complex wound healing process in persistent corneal epithelial defect (PCED).

Kala Pharmaceuticals, Inc., recently announced that it will present data from a previously completed Phase 1b clinical trial of KPI-012 in a poster session at the 2022 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting.

The data support the ongoing development of KPI-012, a novel investigational secretome therapy, to address the complex wound healing process in persistent corneal epithelial defect (PCED). ARVO takes place in Denver, Colorado, May 1-4, 2022 and virtually, May 11-12, 2022.

Kala is a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye.

The accepted abstract is listed below and is now available on the ARVO conference website: https://www.arvo.org/annual-meeting/.

The session is titled “Corneal epithelial biology and repair mechanisms,” and will be presented by Valeria Sánchez-Huerta, M.D., Director General, Asociación para Evitar la Ceguera en México.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) Inside NYEE’s new refractive solutions center with Kira Manusis, MD
(Image credit: Ophthalmology Times) Dilsher Dhoot, MD, on the evolution of geographic atrophy therapy: where are we now?
(Image credit: Ophthalmology Times Europe) Anat Loewenstein, MD, shares insights on the real-world results of remote retinal imaging
(Image credit: Ophthalmology Times) Two-wavelength autofluorescence for macular xanthophyll carotenoids with Christine Curcio, PhD
(Image credit: Ophthalmology Times) FLIO and the brain: Making the invisible visible with Robert Sergott, MD
(Image credit: Ophthalmology Times) Structure-function correlates using high-res OCT images with Karl Csaky, MD, PhD
(Image credit: Ophthalmology Times) SriniVas Sadda, MD, on high-res OCT of atrophic and precursor lesions in AMD
(Image credit: Ophthalmology Times) Christine Curcio, PhD, shares histology update supporting review software and revised nomenclature for <3 μm OCT
1 expert is featured in this series.
1 expert is featured in this series.
© 2025 MJH Life Sciences

All rights reserved.